Abstracts tagged "Antibodies"

Abstract Number: 730 • 2014 ACR/ARHP Annual Meeting
Prediction of Cardiac and Vascular Events in Systemic Sclerosis: Input from Endothelin-1 Type a Receptor Antibodies
Jerome Avouac¹, Gabriela Riemekasten², Christophe Meune³, Barbara Ruiz⁴ and Yannick Allanore¹, ¹Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ²Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, ³Paris 13 University, University Hospital of Paris-Seine-Saint-Denis, Cardiology Department, Bobigny, France, ⁴Paris Descartes University, INSERM U1016, Institut Cochin, Sorbonne Paris Cité, Paris, France
Background/Purpose: Cardiac and peripheral microvascular alterations are key features of systemic sclerosis (SSc). We have previously reported that angiogenic markers can predict the cardiovascular outcomes…
Abstract Number: 320 • 2014 ACR/ARHP Annual Meeting
Autoantibodies in Juvenile Systemic Sclerosis
Katharine Moore^1,2, J. Lee Nelson^3,4, Marvin J. Fritzler⁵, Marisa S. Klein-Gitelman⁶, Ann M. Reed⁷, Tzielan C. Lee⁸ and Anne M. Stevens^1,9, ¹Pediatrics, University of Washington, Seattle, WA, ²Pediatric Rheumatology, Seattle Children's Hospital, Seattle, WA, ³University of Washington, Seattle, WA, ⁴Fred Hutchinson Cancer Research Center, Seattle, WA, ⁵Mitogen Advanced Diagnostics Laboratory, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, ⁶Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁷Rheumatology, Mayo Clinic, Rochester, MN, ⁸Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁹Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: There are no known biomarkers for organ involvement, response to therapy, or prognosis in juvenile systemic sclerosis (jSSc). In adults with systemic sclerosis, a…
Abstract Number: 2924 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, Richard B. Warren³, Christopher E.M Griffiths³, Ann W. Morgan⁴, Anthony G. Wilson⁵, Kimme L. Hyrich¹, John Isaacs⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³Dermatology Centre, University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland, ⁶Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose Up to 40% of RA patients on anti-TNF treatment fail to respond either due to primary inefficacy or loss of response. One explanation is…
Abstract Number: 2771 • 2014 ACR/ARHP Annual Meeting
PET-CT Imaging and Association of Ferritin Autoantibodies in Polymyalgia Rheumatica
Niklas Thomas Baerlecken¹, Torsten Witte², Marco Amedeo Cimmino³ and Dario Camellino⁴, ¹Clinical Immunology and Rheumatology, MD, Hannover, Germany, ²Medical School Hannover, MD, Hanover, Germany, ³Clinica Reumatologica, Università di Genova, Genova, Italy, ⁴Dipartimento Medicina Interna, Clinica Reumatologica, Genova, Italy
Background/Purpose Previously we described antibodies against ferritin heavy chain peptide (anti-FHCP) in sera of patients with giant cell arteritis (GCA) and/or polymyalgia rheumatic (PMR) before…
Abstract Number: 2916 • 2013 ACR/ARHP Annual Meeting
Anti-Fibrillarin Antibodies Are Associated With More Severe Gastrointestinal Involvement and Poorer Survival
Shervin Assassi¹, Marie Hudson², Maureen D. Mayes³, Jennifer Walker⁴, Murray Baron^5,6, Wendy Stevens⁷, Karen Patterson⁸, Tiffany Graham¹, Solene Tatibouet⁹, James Wick¹⁰, Matt Stephenson¹¹ and Marvin J. Fritzler¹¹, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³University of Texas Health Science Center at Houston, Houston, TX, ⁴Flinders Medical Centre, Adelaide, Australia, ⁵McGill University, Montreal, QC, Canada, ⁶MCGill University, Montreal, QC, Canada, ⁷Rheumatology, St Vincent's Hospital, Melbourne, Australia, ⁸Institute of Medical and Veterinary Science, North Adelaide, Australia, ⁹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹⁰Department of medicine, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-fibrillarin (U3-RNP) antibodies (AFA) are a relatively specific biomarker for systemic sclerosis (SSc). Previous studies have indicated a higher prevalence of AFA among African…
Abstract Number: 2593 • 2013 ACR/ARHP Annual Meeting
The Prognosis Of Scleroderma Renal Crisis In RNA-Polymerase III Antibody (ARA) Positive Compared To ARA Negative Patients
Bernadette Lynch¹, Henry Penn², Jennifer Harvey³, Aine Burns⁴ and Christopher P. Denton⁵, ¹Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, ²Northwick Park Hospital, Harrow, United Kingdom, ³Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁴Department of Nephrology, The Royal Free Hospital, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC) usually presenting with accelerated hypertension and acute kidney injury (AKI) is one of the most severe complications of Systemic Sclerosis…
Abstract Number: 2588 • 2013 ACR/ARHP Annual Meeting
Pulmonary Hypertension In Patients With Anti-U1-RNP Antibodies
Vincent Sobanski¹, Bernadette Lynch², Benjamin E. Schreiber³, Svetlana I. Nihtyanova⁴, Jennifer Harvey⁵, Clive Handler⁶, Christopher P. Denton⁷ and John G. Coghlan⁸, ¹Department of Rheumatology, Royal Free Hospital, London, United Kingdom, ²Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, ³Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ⁴Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ⁵Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁶Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, ⁷Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ⁸National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of morbidity and mortality in patients with connective tissue diseases (CTD). Patients with anti-U1-RNP antibodies belong to…
Abstract Number: 2508 • 2013 ACR/ARHP Annual Meeting
Clinical and Serological Discordance In The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Cohort
Murray B. Urowitz¹, Dafna D. Gladman¹, Nicole Anderson¹ and Systemic Lupus Erythematosus International Collaborating Clinics SLICC², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Anti-DNA antibodies and serum complement levels are considered important biomarkers for disease activity in SLE. Despite this many SLE patients present serologically active (positive…
Abstract Number: 2030 • 2013 ACR/ARHP Annual Meeting
Comparative Immunogenicity Of Tumor Necrosis Factor Inhibitors: Impact On Clinical Efficacy and Tolerability In The Management Of Autoimmune Diseases: A Systematic Review and Meta-Analysis
Sarah Thomas¹, Nabeel Borazan², Lewei Duan³, Nashla Barroso⁴, Sara Taroumian⁵, Banjamin Kretzmann⁶, Ricardo Bardales⁶ and Daniel Furst¹, ¹Medicine, University of California, Los Angeles, Los Angeles, CA, ²Medicine, Rheumatology UCLA, Los Angeles, CA, ³David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁴Division of Rheumatology, David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁵Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ⁶Rheumatology, University of California Los Angeles, los angeles, CA

AbstractBackground/Purpose: Tumor necrosis factor inhibitors (TNFi) are a mainstay in the treatment of rheumatoid arthritis (RA), as well as the management of spondyloarthritis (SpA) and…
Abstract Number: 1594 • 2013 ACR/ARHP Annual Meeting
Cognitive Dysfunction, Depression and Anti N-Methyl-D-Aspartate Receptor Antibodies and Anti- Ribosomal P In Systemic Lupus Erythematosus Patients In Argentina
Graciela Gómez¹, Judith Sarano², Maria de los Angeles Gargiulo¹, María Victoria Collado², Lorena Suarez¹, Daniel Fadel³, Alexandra Panopulos⁴ and Marina Khoury⁵, ¹Rheumatology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ²Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ³Psychiatric, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁴Neurology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁵Research and Teaching, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina
Background/Purpose: Cognitive dysfunction (CD) and depression (D) are common manifestations of neuropsychiatric systemic lupus erythematosus (SLE) and they have been linked to antibodies (abs) like…
Abstract Number: 1251 • 2013 ACR/ARHP Annual Meeting
Collagen Antibodies Induce Pain-Like Behavior In Mice Without Signs Of Inflammation
Gustaf Wigerblad¹, Katalin Sandor¹, Kutty Selva Nandakumar², Rikard Holmdahl³ and Camilla Svensson¹, ¹Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ²Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, ³Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Collagen Antibody Induced Arthritis (CAIA) is a mouse model of rheumatoid arthritis (RA). It is induced by injection of a cocktail of monoclonal antibodies…
Abstract Number: 920 • 2013 ACR/ARHP Annual Meeting
Fms-Like Tyrosine Kinase 3 Signaling Is Essential For Differentiation Of Antigen Specific Plasma Cells During Experimental Arthritis
Mattias Svensson¹, Kersti Månsson¹, Karin Andersson¹, Mats Bemark², Mikael Brisslert¹ and Maria Bokarewa¹, ¹Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ²Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Signaling through the tyrosine kinase receptor Flt3 plays an important role in early B-cell development. Mice lacking either Flt3 or its ligand (Flt3L) have…
Abstract Number: 714 • 2013 ACR/ARHP Annual Meeting
Combination Blocking Of Interleukin-6 and Interleukin-21 In Experimental Arthritis Inhibits Their Redundant Role In T Helper 17-Driven Joint Pathology
Debbie M. Roeleveld¹, Marije I. Koenders², Renoud J. Marijnissen^1,3, Cheryl L. Nickerson-Nutter⁴, Fons A. van de Loo¹ and Wim B. van den Berg⁵, ¹Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, Netherlands, ⁴Immunology and Autoimmunity, Pfizer, Cambridge, MA, ⁵Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Both IL-6 and IL-21 have been described to drive in vitro Th17 differentiation in the presence of TGF-β. We explored whether also in vivo…
Abstract Number: 674 • 2013 ACR/ARHP Annual Meeting
Systemic Sclerosis Disease Subset Is a Better Predictor Of Long Term Outcome Than Autoantibody Profile
Svetlana I. Nihtyanova¹, Voon H. Ong² and Christopher P. Denton³, ¹Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ²Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, ³Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom
Background/Purpose: Disease subset has been shown to strongly correlate with survival and risk of organ complications in patients with systemic sclerosis (SSc). Nevertheless evidence in…
Abstract Number: 38 • 2013 ACR/ARHP Annual Meeting
Use Of An In Vitro Whole Blood Depletion ASSAY To Compare The Efficacy Of B CELL Depleting Agents In Patients With Systemic LUPUS Erythematosus
Venkat Reddy¹, Geraldine Cambridge², D.A. Isenberg³, Mark Cragg⁴ and Maria Leandro⁵, ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom, ⁵Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Variability in clinical response to B-cell depletion therapy (BCDT) with the anti-CD20mAb rituximab (RTX) has been well described in Systemic Lupus Erythematosus (SLE). Poor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].